28 June 2023
Cizzle Biotechnology Holdings Plc
("Cizzle Biotechnology" or the "Company")
Result of AGM
Cizzle Biotechnology, the UK-based diagnostics developer, announces that at the Annual General Meeting ("AGM") of the Company held earlier today, all resolutions were voted on by a show of hands and were passed.
The proxy votes cast in respect of the resolutions were as follows:
| Resolution | For | Against | Votes withheld | ||
| Total votes | % | Total votes | % |
| |
| 1. To receive the Company's annual report and accounts for the year ended 31 December 2022 | 89,757,080 | 97.11 | 2,672,935 | 2.89 | 1,661,693 |
| 2. To approve the Directors' Remuneration Report |
88,827,568
| 96.10 | 3,602,447 | 3.90 | 1,661,693 |
| 3. To re-appoint Allan John Syms as a Director of the Company |
88,827,578
| 96.14 |
3,568,237
| 3.86 | 1,695,893 |
| 4. To re-appoint PKF Littlejohn LLP as auditor of the Company | 88,861,778 | 96.14 | 3,568,237 | 3.86 |
1,661,693
|
| 5. To authorise the Directors to determine the auditor's remuneration | 88,861,778 | 96.14 | 3,568,237 | 3.86 |
1,661,693
|
| 6. Authorises the Directors to allot shares in the Company or to grant rights to subscribe for, or to convert any security into, shares in the Company | 88,661,778 | 95.92 | 3,768,237 | 4.08 | 1,661,693 |
| 7. Authorise the Directors to allot equity securities disapplying pre-emption rights | 88,823,568 | 96.10 | 3,606,437 | 3.90 | 1,661,703 |
| 8. That General Meetings may be called on not less than 14 days' notice | 88,861,778 | 96.14 | 3,568,237 | 3.86 | 1,661,693 |
Enquiries:
| Cizzle Biotechnology Holdings plc | Via IFC Advisory |
| Allan Syms (Executive Chairman) | |
| Allenby Capital Limited | +44(0) 20 33285656 |
| John Depasquale | |
| Alex Brearley | |
| Novum Securities Limited | +44(0) 20 7399 9400 |
| Colin Rowbury Jon Bellis | |
| IFC Advisory Limited | +44(0) 20 3934 6630 |
| Tim Metcalfe | cizzle@investor-focus.co.uk |
| Florence Chandler | |
Notes to Editors:
About Cizzle Biotechnology
Cizzle Biotechnology is developing a blood test for the early detection of lung cancer. Cizzle Biotechnology is a spin- out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer.
For more information, please see https://cizzlebiotechnology.com
You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
